{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:49:38Z","timestamp":1780397378636,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2022206295"],"award-info":[{"award-number":["H2022206295"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Science and Technology Research Program of Hebei Provincial Health Commission","award":["20230991"],"award-info":[{"award-number":["20230991"]}]},{"DOI":"10.13039\/501100006090","name":"Industry-Academic Cooperation Foundation of Kyungnam University","doi-asserted-by":"publisher","award":["CXY2024020"],"award-info":[{"award-number":["CXY2024020"]}],"id":[{"id":"10.13039\/501100006090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hebei Province Finance Department Project","award":["LS202214"],"award-info":[{"award-number":["LS202214"]}]},{"name":"Industry University Research Cooperation Special Project","award":["CXY2024020"],"award-info":[{"award-number":["CXY2024020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07616-7","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T02:32:16Z","timestamp":1723861936000},"page":"1375-1386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared with Vitamin K Antagonists in Patients with Atrial Fibrillation and Type 2 Valvular Heart Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Xiaoyun","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1221-3698","authenticated-orcid":false,"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"7616_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1146\/annurev-med-042921-122533","volume":"74","author":"MF Eleid","year":"2023","unstructured":"Eleid MF, Nkomo VT, Pislaru SV, Gersh BJ. Valvular heart disease: new concepts in pathophysiology and therapeutic approaches. Annu Rev Med. 2023;74:155\u201370. https:\/\/doi.org\/10.1146\/annurev-med-042921-122533.","journal-title":"Annu Rev Med"},{"issue":"1","key":"7616_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/ijms23010006","volume":"23","author":"M Sagris","year":"2021","unstructured":"Sagris M, Vardas EP, Theofilis P, et al. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021;23(1):6. https:\/\/doi.org\/10.3390\/ijms23010006.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"7616_CR3","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/cir.0000000000001062","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e876\u201394. https:\/\/doi.org\/10.1161\/cir.0000000000001062.","journal-title":"Circulation"},{"issue":"5","key":"7616_CR4","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1253\/circj.CJ-19-1158","volume":"84","author":"K Doi","year":"2020","unstructured":"Doi K, Ogawa H, Ishigami K, et al. Impact of valvular heart disease on mortality, thromboembolic and cardiac events in japanese patients with atrial fibrillation - the Fushimi AF Registry. Circ J. 2020;84(5):714\u201322. https:\/\/doi.org\/10.1253\/circj.CJ-19-1158.","journal-title":"Circ J"},{"issue":"13","key":"7616_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jacep.2020.07.005","volume":"6","author":"L Melgaard","year":"2020","unstructured":"Melgaard L, Overvad TF, Jensen M, et al. Thromboembolic risk in nonanticoagulated patients with atrial fibrillation and valvular heart disease. JACC Clin Electrophysiol. 2020;6(13):1672\u201382. https:\/\/doi.org\/10.1016\/j.jacep.2020.07.005.","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"7616_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/europace\/eux240","volume":"19","author":"GYH Lip","year":"2017","unstructured":"Lip GYH, Collet JP, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology working group on thrombosis, endorsed by the ESC working group on valvular heart disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE). Europace. 2017;19(11):1757\u20138. https:\/\/doi.org\/10.1093\/europace\/eux240.","journal-title":"Europace"},{"issue":"3","key":"7616_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11239-018-1698-y","volume":"46","author":"AB Hughey","year":"2018","unstructured":"Hughey AB, Gu X, Haymart B, et al. Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the \u201creal-world\u201d Michigan anticoagulation quality improvement initiative (MAQI(2)) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Thromb Thrombolysis. 2018;46(3):316\u201324. https:\/\/doi.org\/10.1007\/s11239-018-1698-y.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"7616_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","volume":"38","author":"A Amin","year":"2014","unstructured":"Amin A, Deitelzweig S, Jing Y, et al. Estimation of the impact of warfarin\u2019s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38(2):150\u20139. https:\/\/doi.org\/10.1007\/s11239-013-1048-z.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"7616_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/cir.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024;149(1):e1\u2013156. https:\/\/doi.org\/10.1161\/cir.0000000000001193.","journal-title":"Circulation"},{"issue":"551","key":"7616_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/pgmj.47.551.599","volume":"47","author":"HA Fleming","year":"1971","unstructured":"Fleming HA, Bailey SM. Mitral valve disease, systemic embolism and anticoagulants. Postgrad Med J. 1971;47(551):599\u2013604. https:\/\/doi.org\/10.1136\/pgmj.47.551.599.","journal-title":"Postgrad Med J"},{"issue":"13","key":"7616_CR11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1300615.","journal-title":"N Engl J Med"},{"issue":"11","key":"7616_CR12","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","volume":"387","author":"SJ Connolly","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387(11):978\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2209051.","journal-title":"N Engl J Med"},{"issue":"7","key":"7616_CR13","doi-asserted-by":"publisher","first-page":"EVIDoa2300067","DOI":"10.1056\/EVIDoa2300067","volume":"2","author":"TY Wang","year":"2023","unstructured":"Wang TY, Svensson LG, Wen J, et al. Apixaban or warfarin in patients with an on-x mechanical aortic valve. NEJM Evid. 2023;2(7):EVIDoa2300067. https:\/\/doi.org\/10.1056\/EVIDoa2300067.","journal-title":"NEJM Evid"},{"issue":"2","key":"7616_CR14","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1055\/s-0039-1692202","volume":"3","author":"MC Vedovati","year":"2019","unstructured":"Vedovati MC, Reboldi G, Agnelli G, Verdecchia P. Type 2 valvular heart disease affects decision making for anticoagulation in patients with atrial fibrillation: the UMBRIA-fibrillazione atriale prospective study. TH Open. 2019;3(2):e157\u201364. https:\/\/doi.org\/10.1055\/s-0039-1692202.","journal-title":"TH Open"},{"issue":"11","key":"7616_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/m14-2385.","journal-title":"Ann Intern Med"},{"issue":"4","key":"7616_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost"},{"issue":"23","key":"7616_CR17","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","volume":"385","author":"NM Van Mieghem","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2111016.","journal-title":"N Engl J Med"},{"issue":"10","key":"7616_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMc2035891","volume":"384","author":"AR Duraes","year":"2021","unstructured":"Duraes AR, Bitar YSL. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2021;384(10):975. https:\/\/doi.org\/10.1056\/NEJMc2035891.","journal-title":"N Engl J Med"},{"issue":"11","key":"7616_CR19","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","volume":"69","author":"R De Caterina","year":"2017","unstructured":"De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2017;69(11):1372\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.031.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"7616_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/circulationaha.115.020950","volume":"134","author":"MD Ezekowitz","year":"2016","unstructured":"Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation. 2016;134(8):589\u201398. https:\/\/doi.org\/10.1161\/circulationaha.115.020950.","journal-title":"Circulation"},{"issue":"2","key":"7616_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","volume":"16","author":"AR Dur\u00e3es","year":"2016","unstructured":"Dur\u00e3es AR, de Souza RP, de Almeida NB, et al. Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D. 2016;16(2):149\u201354. https:\/\/doi.org\/10.1007\/s40268-016-0124-1.","journal-title":"Drugs R D"},{"issue":"8","key":"7616_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/circulationaha.114.014807","volume":"132","author":"A Avezum","year":"2015","unstructured":"Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2015;132(8):624\u201332. https:\/\/doi.org\/10.1161\/circulationaha.114.014807.","journal-title":"Circulation"},{"issue":"47","key":"7616_CR23","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","volume":"35","author":"G Breithardt","year":"2014","unstructured":"Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014;35(47):3377\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehu305.","journal-title":"Eur Heart J"},{"issue":"5","key":"7616_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/clc.23178","volume":"42","author":"PO Guimar\u00e3es","year":"2019","unstructured":"Guimar\u00e3es PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42(5):568\u201371. https:\/\/doi.org\/10.1002\/clc.23178.","journal-title":"Clin Cardiol"},{"issue":"13","key":"7616_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1161\/circulationaha.116.026714","volume":"135","author":"AP Carnicelli","year":"2017","unstructured":"Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017;135(13):1273\u20135. https:\/\/doi.org\/10.1161\/circulationaha.116.026714.","journal-title":"Circulation"},{"issue":"22","key":"7616_CR26","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","volume":"26","author":"R Nieuwlaat","year":"2005","unstructured":"Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on atrial fibrillation. Eur Heart J. 2005;26(22):2422\u201334. https:\/\/doi.org\/10.1093\/eurheartj\/ehi505.","journal-title":"Eur Heart J"},{"issue":"10","key":"7616_CR27","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3390\/jcm8101624","volume":"8","author":"I Moon","year":"2019","unstructured":"Moon I, Lee SR, Choi EK, et al. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Clin Med. 2019;8(10):1624. https:\/\/doi.org\/10.3390\/jcm8101624.","journal-title":"J Clin Med"},{"key":"7616_CR28","doi-asserted-by":"publisher","unstructured":"de Souza Lima Bitar Y, Neto MG, Filho JAL et al. Comparison of the new oral anticoagulants and warfarin in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Drugs R D. 2019;19(2):117\u201326. https:\/\/doi.org\/10.1007\/s40268-019-0274-z.","DOI":"10.1007\/s40268-019-0274-z"},{"issue":"47","key":"7616_CR29","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","volume":"35","author":"R De Caterina","year":"2014","unstructured":"De Caterina R, Camm AJ. What is \u2018valvular\u2019 atrial fibrillation? A reappraisal Eur Heart J. 2014;35(47):3328\u201335. https:\/\/doi.org\/10.1093\/eurheartj\/ehu352.","journal-title":"A reappraisal Eur Heart J"},{"issue":"8","key":"7616_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40266-017-0476-4","volume":"34","author":"AM Urbaniak","year":"2017","unstructured":"Urbaniak AM, Str\u00f8m BO, Krontveit R, Svanqvist KH. Prescription patterns of non-vitamin K oral anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation between 2012\u20132015: a study from the Norwegian prescription database. Drugs aging. 2017;34(8):635\u201345. https:\/\/doi.org\/10.1007\/s40266-017-0476-4.","journal-title":"Drugs aging"},{"issue":"9","key":"7616_CR31","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/bcp.13299","volume":"83","author":"SY Loo","year":"2017","unstructured":"Loo SY, Dell\u2019Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096\u2013106. https:\/\/doi.org\/10.1111\/bcp.13299.","journal-title":"Br J Clin Pharmacol"},{"key":"7616_CR32","doi-asserted-by":"publisher","first-page":"675200","DOI":"10.3389\/fcvm.2021.675200","volume":"8","author":"Y Wu","year":"2021","unstructured":"Wu Y, Zhang C, Gu ZC. Cost-effectiveness analysis of direct oral anticoagulants vs vitamin K antagonists in the elderly with atrial fibrillation: insights from the evidence in a real-world setting. Front Cardiovasc Med. 2021;8:675200. https:\/\/doi.org\/10.3389\/fcvm.2021.675200.","journal-title":"Front Cardiovasc Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07616-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07616-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07616-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:01:17Z","timestamp":1766127677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07616-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7616"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07616-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"5 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used a meta-analysis approach with data derived from previously published studies that were systematically statistically integrated and analyzed. No ethical review or informed consent was required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The data involved had been publicly released and did not involve direct intervention or collection of personal information from new participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants should appear in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}